MOTS-c Peptide: Status, Evidence and Sellers

MOTS-c is a mitochondrial-derived peptide, sixteen amino acids long, encoded not in the cell nucleus but within the 12S rRNA region of mitochondrial DNA. It was first described in 2015, reported to support metabolic balance and, in mice, to blunt the obesity and insulin resistance that a rich diet produces [1]. Blood levels climb after physical activity, and its biology runs alongside what exercise does to metabolism. That is how it came to be marketed as an exercise mimetic.

The marketing has outrun the evidence by a considerable distance. It holds no FDA approval for anything, and nobody has published a randomized human trial of it for weight loss; a direct PubMed search turns up none. Every striking result about metabolism or exercise capacity traces back to mice and cell culture. What human studies exist track it in the bloodstream as a marker of exercise or of aging; not one gives it as a drug. The sales copy fills the gap between those biomarker studies and a treatment trial, which nobody has published.

It is translated from a short open reading frame inside the mitochondrial 12S ribosomal RNA gene, which sets it apart from the overwhelming majority of proteins, since those are encoded in nuclear DNA. Once made, it can act locally within the mitochondria and, under metabolic stress, move into the nucleus, and the proposal there is that it takes a hand in regulating genes that govern metabolism and antioxidant defense [2].

Mouse work has shown it helping regulate fat-tissue homeostasis and guarding against the metabolic damage that follows removal of the ovaries [4]. A 2021 Nature Communications paper cast it as a mitochondrially encoded regulator, switched on by exercise, of age-related physical decline and muscle upkeep, with its headline findings once again produced in mice [3]. This is real, actively studied mitochondrial biology. Nobody has shown that it takes weight off humans.

The 2015 Cell Metabolism paper that started this reported improved insulin sensitivity and protection against diet-induced obesity in mice [1]. Later mouse work extended it to fat-tissue regulation [4], and the 2021 study tied it to exercise capacity and muscle maintenance, again in mice [3]. These three are what get cited to sell it online, and all three are rodent studies.

The human literature exists but answers a different question. One 2021 study put people through a single exercise session and measured mitochondrial-derived peptides in the blood afterward; humanin rose after cycling, while this one only showed a trend toward rising [5]. At most that makes it a candidate exercise biomarker. It does not test whether giving it to someone causes weight loss. A PubMed search for a human randomized trial using it to treat obesity comes back empty. Reviews of mitochondrial-derived peptides in aging treat it as a promising research target whose levels fall with age, while stating that the therapeutic case in humans is unproven [6].

No human dose has been established or clinically validated. Since no human randomized trial has tested it for weight loss or metabolic benefit, no dose has been shown safe or effective in people, and the figures circulating on vendor sites and forums have nothing behind them. This page publishes no dosing protocol, because printing one would imply a validated regimen exists, and none does.

It carries no FDA approval for any human indication and does not appear in DailyMed. What sells online is almost all research chemical, stamped with a not-for-human-consumption label, the disclaimer that lets a vendor ship a vial without answering to the rules on marketing a drug. Nothing here is regulated, so no agency verifies what is in the vial: whether it is the right molecule, how pure or sterile it is, or the dose. Injecting something unverified brings real risk (contaminants, infection, a dose nobody has measured), and no proven human benefit sits on the other side of that ledger.

The clinics listed on this site that offer it prescribe through a licensed clinician rather than shipping a research-use vial, so someone qualified is watching. That oversight does not settle where the peptide comes from. MOTS-c is not on FDA's list of bulk substances pharmacies may compound with, and FDA's briefing for its July 2026 compounding advisory committee meeting weighed against adding it. Since October 28, 2026, though, an interim HHS policy says HHS does not intend to take enforcement action against state-licensed pharmacies and physicians that compound MOTS-c acetate as a subcutaneous or intramuscular injection, from tested bulk peptide out of an FDA-registered facility, as a single ingredient, with serious adverse events reported to FDA [7]. That makes the source more traceable. It approves nothing. Nor does oversight change the evidence. Even with a doctor involved, no human trial has shown it takes weight off, so treat it as the unproven off-label compounded peptide it is and raise the absence of efficacy data with your prescriber before you start rather than after.